Healthcare: life sciences in United States
Arnold & Porter has one of the strongest global life sciences practices, covering a broad range of product areas, including regulatory, antitrust, white collar, IP, product liability and transactional capabilities. Recent mandates include advising AbbVie on its $63bn acquisition of Allergan; advising AstraZeneca in the negotiation of an exclusive research collaboration and licensing agreement to co-develop five engineered oncolytic vaccinia virus candidates with Transgene; and successfully defending Boston Scientific against seven patent infringement claims brought by Nevro in the spinal cord stimulation space. The team is jointly led by FDA specialists Daniel Kracov and Allison Shuren, and includes Jeffrey Handwerker who is recommended for pharmaceutical pricing and investigations, commercial litigation involving the pharmaceutical, medical products and biotechnology industries; New York-based Arthur Brown who is particularly experienced in product liability, mass tort and commercial litigation cases; IP litigator Deborah Fishman who has a particular emphasis on biopharmaceutical and medical device patent litigation; and Lowell Dashefsky who handles a broad range of big-ticket transactional mandates. Kristin Hicks, Murad Hussain, Mahnu Davar, recently promoted partner Vinita Kailasanath, and counsels Bryan Godfrey and Abeba Habtemariam are also highly recommended. All individuals mentioned above are based in New York and Washington DC.
Other key lawyers:
Pharmaceutical Manufacturers Association
Bristol-Myers Squibb Company
Novartis Pharmaceuticals Corp.
Eli Lilly & Co.
Boston Scientific Corporation
- Representing PhRMA in its response to the HHS’s request for information concerning the President’s Blueprint to reduce drug prices.
- Represented Endo Pharmaceuticals in some of its largest product liability litigation involving testosterone products and in state and federal litigation regarding FDA-approved prescription opioid medications.
- Defended Bayer against a complaint alleging claims of monopolization, tying, and exclusive dealing with respect to the company’s sales agreements relating to flea and tick products containing the active ingredient imidacloprid.
- Successfully represented Bristol-Myers Squibb and Sanofi in matters ranging from personal product liability litigation, to False Claims Act qui tam actions, and pharmaceutical antitrust litigation.
- Acted for Novartis Pharmaceuticals in several high-profile white collar, antitrust, corporate, and IP litigation matters.
Hogan Lovells US LLP advises across the full life cycle of a product or business, from initial clinical trials to off-patent strategy to business development, through financing to defending bet-the-companty litigation. The cross-practice team advises clients on artificial intelligence, cells, tissue and gene therapies, 3D printing, biosimilars and royalty financing. Adam Golden and Asher Rubin focus on multibillion-dollar cross-border transactions, and are based in New York and Baltimore respectively. The team has a large number of highly regarded regulatory specialists. Among them, Washington DC-based David Fox maintains a leading practice in the regulation of new drugs, biologics and combination products, and is frequently involved in bringing novel products through the FDA review process; Philadelphia-based Janice Hogan focuses on expediting the approval of high technology medical devices; Philip Katz heads the pharmaceutical and biotechnology regulatory practice from its Washington DC office, and is recommended alongside Jonathan Kahan who has notable experience in obtaining FDA market clearance or approval of novel medical devices for medical technology and diagnostics companies, as well as representing clients in FDA enforcement actions. Lauren Colton focuses on product liability cases, and is representing Bristol-Myers Squibb in over 2500 lawsuits and claims filed by patients who allege that their use of the atypical antipsychotic, Abilify, caused them to develop compulsive gambling and other impulse control disorders. Further names to note include Washington DC-based Susan Lee, Adriana Tibbitts, counsel Anishiya Abrol, and senior associates Justin Yu and Blake Wilson who are based in Silicon Valley and Philadelphia.
Other key lawyers:
‘The team understands client’s needs and risks based on the product and the company and customize all for us. They very much dig into the science of our product and enhances our thinking and the materials we develop‘.
‘The US and European counterparts work really well together and have a great deal of synergies and collaboration. On the international side, we have been able to gain the country-specific expertise we very much needed‘.
‘The quality of the counsel is excellent. In addition, they are able to bring together various expertise areas, when necessary, in a well-coordinated and efficient manner. They work together really well as a team and the resulting advice is not only excellent but comprehensive and well-articulated‘.
‘Eliza Andonova, Susan Lee, and Susan Cook stand out for their understanding of the industry, the quality of their critical thinking and advice, and their responsiveness. They do a wonderful job of analyzing situations and providing practical guidance‘.
The University of Pennsylvania
- Assisted Tesaro with its $5.1bn acquisition by GlaxoSmithKline.
- Advised NextCure, a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases, on its initial public offering and development collaboration with Eli Lilly and Company.
- Advising Biohaven Pharmaceuticals on its interactions with FDA on a range of issues, including approval standards, expedited review programs, orphan drug designation, regulatory exclusivities, and expanded access programs.
- Advising AllerQuest on getting FDA approval for its comprehensive test for penicillin allergy.
- Advising Bristol-Myers Squibb in connection with over 2,500 lawsuits and claims filed by patients who allege that their use of the atypical antipsychotic, Abilify, caused them to develop compulsive gambling and other impulse control disorders.
Cooley LLP's client base includes high-growth and mature companies, as well as entrepreneurs, venture capitalists and financial institutions. The team is particularly well-placed to advise on corporate partnering and licensing, venture financings, capital markets and M&A transaction, as well as IP prosecution, counseling, licensing and litigation, and regulatory and securities litigation. The highly regarded transactional practitioner Barbara Kosacz (Palo Alto) heads the practice with New York-based Ivor Elrifri who chairs the firm's global patent counseling and prosecution practice group. Key names to note for transactional matters include Barbara Borden and Kay Chandler in San Diego, Laura Berezin, Mark Weeks and Kate Hillier in Palo Alto, and Marc Recht in Boston. Mika Reiner Mayer is recommended for patent prosecution and strategic portfolio management for life sciences startups and established companies; Lila Hope specializes in transactions involving complex intellectual property issues, and Marya Postner is particularly experienced in handling strategic alliances between biotechnology and pharmaceutical companies in areas as diverse as collaborative research and the development and marketing of late-stage pharmaceutical products.
Other key lawyers:
- Advised Adaptive Biotechnologies in its worldwide collaboration and license agreement with Genentech in the development, manufacturing and commercialization of novel, neoantigen directed T-cell therapies for cancer using Adaptive’s proprietary T-cell receptor discovery and immune profiling platform.
- Acted for Arvelle Therapeutics in its exclusive licensing agreement with SK Biopharmaceuticals for Arvelle to develop and commercialize cenobamate in Europe.
- Advised Zealand Pharma A/S in its collaboration, exclusive worldwide license agreement and share subscription agreement with Alexion Pharmaceuticals to discover and develop novel peptide therapies for complement-mediated diseases.
- Advised Jazz Pharmaceuticals on its acquisition of Redx Pharma’s pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors.
- Acted for Immune Design, a clinical-stage immunotherapy company, in its $300m sale to Merck.
Goodwin's life sciences group excels in a number of areas, notably: venture capital and early stage financing, capital markets, M&A, collaborations and licensing transactions. Among its recent standout work, the team advised Ipsen on its $1.31bn acquisition of Clementia Pharmaceuticals, handled BlueRock Therapeutics's $1bn acquisition by Bayer, and acted for Relay Therapeutics in the completion of its $400m Series C financing. The team also has significant IP litigation and counseling, commercial litigation and regulatory expertise. The practice group is jointly led by Boston-based Mitchell Bloom, who has a strong reputation advising clients from their launch, through multiple rounds of venture financings, to their initial public offerings, and through corporate and other strategic matters. Also recommended is Kingsley Taft, who counts Semma Therapeutics, Foundation Medicine, Teva Pharmaceuticals, and Moderna Therapeutics as clients. Other names to note include Sam Zucker who joined the Silicon Valley office from Sidley Austin LLP, San Francisco-based Maggie Wong, and Duncan Greenhalgh, who represents venture capital firms in intellectual property matters relating to their portfolio company investments, and also acts for investment banks in connection with capital market transactions. Alexander Varond is a standout senior associate in the team; he focuses on FDA matters.
Other key lawyers:
‘The Goodwin team brings the expertise and horsepower to execute the wide range of transactions that arise for growing companies. Their scale is an invaluable resource, never limiting our ability to pursue ideas that might benefit our business. Their ability to provide a single point of contact combined with subject matter experts for every unique scenario is differentiated relative to other firms with which we’ve worked‘.
‘Maggie Wong is a tireless resource who is always available, provides rapid and actionable feedback, and loops in colleagues as needed for specific expertise. She is willing and able to meet our colleagues at their level of experience and support the execution of simple and complex transactions‘.
‘Mitch Bloom helps us understand the appropriate balance between risk and our objectives‘.
‘In licensing transactions, Noelle Dubiansky and Emily Beman effectively hold client’s ground on important items while working with the clients to find compromises on terms that are consequential to both parties‘.
Third Rock Ventures
- Advised Spark on its definitive merger agreement to be fully acquired by Roche for $4.8bn.
- Advised Moderna on its $604m initial public offering.
- Acted for Arvelle in its licensing agreement with SK Biopharmaceuticals.
- Advised Relay Therapeutics on the completion of its $400 million Series C financing round.
- Representing Fresenius Medical Care North America in a range of regulatory projects, including promotion and marketing of drugs and medical devices and regulatory due diligence on target companies in cutting-edge commercial transactions.
King & Spalding LLP advises some of the world's leading pharmaceutical, biotechnology, and medical device manufacturers, and is noted in particular for its strength in complex regulatory matters, acting for clients at every stage of the product lifecycle, from IP protection and clinical trials, through product approvals and post-approval regulatory and transactional matters, as well as in litigation. Of recent note, the IP team secured a win for Galderma in a Hatch-Waxman litigation against Sun Pharmaceuticals. Product liability litigation, government investigations, and congressional investigations are also strengths of the team. The life sciences and healthcare industry group is jointly led by Mark Polston and Nikki Reeves from the Washington DC office, which also includes FDA specialists Lisa Dwyer, Seth Lundy, Mark Brown and John Shakow; patent litigator Gerald Flattmann; and white-collar crime specialist Mark Jensen. Preeya Pinto, Brian Bohnenkamp and counsel Jessica Ringel are also recommended for regulatory matters.
Other key lawyers:
‘K&S is cohesive and the work flows together seamlessly. Each member knows their role and area of expertise and relies upon other team members when topics extend out of their area of expertise. Working with K&S give me a feeling that I am fully supported during deposition preps – and that they know the specific field I am working within. K&S tailors the work to the field needed, and brings in lawyers with appropriate background to ensure success‘.
‘Their internal discussions gave the ability for the customer to make an informed decision as to how to move forward. The team addresses every little detail which allows for a professional outcome‘.
Bristol Myers Squibb
Hope Medical Enterprises (d/b/a Hope Pharmaceuticals)
Novo Nordisk Pharmaceuticals
- Represented Allergan in an unfair competition and false advertising lawsuit against Imprimis Pharmaceuticals.
- Representing GlaxoSmithKline in a product liability litigation relating to the cause of birth defect of Zofran.
- Represented Galderma Laboratories in several Hatch-Waxman patent litigation regarding Oracea, a pharmaceutical treatment for rosacea.
- Acting for patent owner Alexion in several inter partes review (IPR) proceedings, brought by Amgen, challenging patents covering Alexion’s biologic product Soliris.
- Advising Actelion Pharmaceuticals, subsequently acquired by Johnson & Johnson, in one of the most widely publicized, ongoing industry-wide DOJ investigations focused on Anti-Kickback Statute and False Claims Act issues raised by pharmaceutical manufacturer donations to charitable patient assistance foundations.
With an impressive client roster of blue-chip pharmaceutical, biotech and medical devices companies, Latham & Watkins LLP has excellent transactional credentials including buy- and sell-side M&A, capital markets transactions, and commercial deals including high-value licensing. The team handled a steady flow of multimillion-dollar capital markets transactions for clients including Guardant Health, Gritstone Oncology, Gossamer Bio and Satsuma Pharmaceuticals. Recent highlights include representing Agenus in its $1.7bn strategic alliance with Gilead Sciences and acting for Puma Biotechnology and certain of its executives in a securities class action and shareholder derivative suit filed in the US District Court for the Central District of California. Nathan Ajiashvili is particularly recommended for advising financial institutions and public and private companies on equity and debt capital markets transactions, as are Alan Mendelson, Brian Cuneo, Mark Roeder, Cheston Larson and Peter Handrinos. Judith Hasko handles licensing, joint ventures and other technology and IP-based transactions, and John Manthei focuses on regulatory matters and recently represented Catalyst Pharmaceuticals in suing the FDA over approval of cheaper rival drug Ruzurgi. The team is spread across New York, Silicon Valley, Boston, San Diego, Washington DC, and Orange County.
Swedish Orphan Biovitrum (“Sobi”)
Inspire Medical Systems
Daiichi Sankyo Co.
- Advised JP Morgan as financial advisor to Takeda Pharmaceuticals on its $60bn acquisition of Shire.
- Advised Ra Pharmaceuticals, a clinical-stage biopharmaceutical company, on its £2.1bn sale to UCB Pharma, a multinational biopharmaceutical company headquartered in Belgium.
- Advised Amgen on its $2.7bn acquisition of a 20.5% stake in BeiGene as well as a concurrent strategic collaboration in which BeiGene will commercialize and advance 20 medicines from Amgen’s oncology pipeline in China and globally.
- Acted for Daiichi Sankyo in its $6.9bn global collaboration with AstraZeneca for an antibody-drug conjugate to treat cancer.
- Successfully represented Merck, Amgen and Eli Lilly in the US District Court for th District of Columbia invalidating a federal rule that would have required the companies to include their wholesale list prices when advertising their drugs on television.
Though it is best-known for its pre-eminent transactional capability spanning major global M&A, collaboration, licensing, and IPO, Morgan, Lewis & Bockius LLP is also a strong performer in patent protection and litigation, commercial litigation, and FDA regulatory issues. Its impressive client roster features pharmaceuticals, biotechnology, medical devices and precision medicine companies, as well as private equity investors and other financial firms that focus on life sciences. The practice is jointly led by FDA regulatory specialist Kathleen Sanzo (Washington DC), IP practitioner Jeffry Mann (Boston), Michael Abernathy (Chicago), a key contact for patent, trade secret and antitrust litigation, and Alan Leeds, who acts for clients including biotechnology start-ups, global pharmaceutical companies, and venture capital firms. Other names to note include Benjamin Pensak, who is particularly experienced in handling technology transactions; capital markets and corporate finance partner David Schwartz , who joined from DLA Piper LLP (US) in 2019; and Tony Chan, who advises on a broad range of M&A, private equity and corporate finance mandates. The team lost Randall Sunberg and Oren Livne to Baker McKenzie LLP in 2019.
‘First rate people, extensive knowledge and experience, and dedication to pragmatic advice‘.
‘Michele Buenafe is a top-notch regulatory lawyer who is completely focused on addressing real issues with real world solutions‘.
Tabula Rasa Healthcare
- Acted for Merck in its acquisition of Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis, and autoimmune diseases.
- Advised Regeneron Pharmaceuticals on its collaboration agreement of up to $1bn with Alnylam Pharmaceuticals.
- Advising Perrigo Co., a provider of over-the-counter health and wellness solutions, in two transactions: the $750m acquisition of Ranir and the $185m sale of Perrigo’s animal health division to PetIQ.
- Acted for Xencor in its research and license agreement with Genentech to develop and commercialize novel IL-15 cytokine therapeutics, including XmAb24306, Xencor’s most advanced preclinical cytokine program.
- Advised Rhythm Pharmaceuticals on the closing of its $172.5m public offering of approximately 9.3 million shares of common stock.
Ropes & Gray LLP is a powerhouse for M&A and capital markets transactions, representing pharmaceutical companies and financial institutions investing in the industry. Recent transactional instructions saw the team advising Wright Medical Group on in its pending $4.7bn sale to Stryker Corporation; assisting Vertex Pharmaceuticals with its $175m expanded collaboration with CRISPR Therapeutics and $245m acquisition of Exonics Therapeutics; and acting for the lead underwriters in the $3.3bn IPO for Avantor. Standalone advisory work, licensing transactions and commercial litigation also feature in the firm's recent caseload. Michael Beauvais and Gregory Levine jointly lead the practice from Boston and Washington DC, respectively. Other notable practitioners include Marc Rubenstein, who focuses on corporate and licensing transactions; Silicon-Valley based Megan Baca, a contact for IP transactions; Amanda Austin, who was promoted to the partnership in 2019; and Thomas Danielski, who acts for publicly traded companies and private equity funds and their portfolio companies in public offerings and other strategic transactions.
- Advised TESARO, an oncology biopharmaceutical company, on its $5.1bn sale to GlaxoSmithKline.
- Advised Medtronic, a medical device company, on its $1.64bn acquisition of Mazor Robotics, an Israel-based company focused on the application of robotics technology and guidance for use during spinal procedures.
- Acting for Beam Therapeutics, a company developing precision genetic medicines through CRISPR base editing, since inception, and advises on a variety of financing, licensing, collaboration, and other strategic agreements.
- Advising Vapotherm, a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI technology products that are used to treat patients of all ages suffering from respiratory distress, on its $64.4m IPO and $45m follow-on offering.
- Assisted Goldfinch Bio, a US-based, clinical stage biotechnology company, with its license agreement with Takeda Pharmaceuticals for global rights to a preclinical, peripherally restricted cannabinoid receptor 1 (CB1) monoclonal antibody for the treatment of rare and metabolic kidney diseases.
Covington & Burling LLP
Covington & Burling LLP has a reputation for advising on a range of regulatory matters, as well as on strategic partnerships, collaboration and licensing transactions, and patent litigation. John Hurvitz and Denise Esposito are contacts in the DC office. Peter Safir and Richard Kingham are also recommended.
Dechert LLP regularly advises on cross-border matters, leveraging the expertise of its life sciences teams across the US, Europe and Asia. The practice is jointly led by Andrea Reid, who focuses on IP-driven transactions and patent portfolio management, David Rosenthal, who is particularly experienced in corporate finance, licensing and capital markets transactions, and Mélanie Thill-Tayara in the firm's Paris office. Sheila Birnbaum and Mark Cheffo focus on product liability, mass torts and insurance litigation, and led the 2,250 cases connected to the Opioid litigation for Purdue Pharma. Martin Black and Katherine Helm, based in Philadelphia and New York respectively, successfully represented SpePharm, a subsidiary of Norgine, in a licensing dispute against Eisai. Carl Morales is another name to note in New York; he focuses on prosecuting patent portfolios for FDA-approved or soon-to-be-approved drug products. Other standout highlights include representing Eli Lilly in a patent infringement action by Genentech involving the client’s autoimmune antibody drug Taltz.
Edge Therapeutics (Now PDS Biotechnology)
Eli Lilly and Company
Zyla Life Sciences (formerly Egalet Corporation)
- Advised Ferring Pharmaceuticals in its joint investment alongside Blackstone Life Sciences of over $570m in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in late stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).
- Acting for Pfizer in securing patent protection for Ibrance, an FDA-approved blockbuster oral drug for first line treatment of HR-positive/HER2-negative breast cancer.
- Advised Zyla Life Sciences (formerly known as Egalet Corporation), on its asset purchase agreement to acquire four FDA-approved, non-narcotic pain products from Iroko Pharmaceuticals.
- Representing Eli Lilly and Company in a patent infringement action by Genentech involving Lilly’s autoimmune antibody drug Taltz.
- Advised CVS Health on the antitrust aspects of its $70bn acquisition of US health insurer Aetna.
Backed by the firm's global network, DLA Piper LLP (US) has broad based expertise in product liability, regulatory work, IP disputes and portfolio management, and corporate ad financing transactions. Matthew Holian and Andrew Gilbert jointly lead the practice from Boston and Short Hills, respectively; Holian focuses on litigation, regulatory and enforcement challenges, while Gilbert handles corporate finance, M&A and securities transactions. San Diego-based Lisa Haile is a name to note for patent protection. Loren Brown co-chairs the firm's global litigation practice, and is 'an excellent strategist who masterfully handles the most sensitive and difficult issues'. Cara Edwards, Christopher Campbell and Lucas Przymusinski are also recommended for product liability cases and mass tort litigation. Katie Insogna is a star associate in the practice group.
Other key lawyers:
‘DLA Provide seamless legal expertise in all areas of biotechnology from raising equity, to business development to IP to real estate transactions‘.
‘The team has extensive experience with both litigation and regulatory issues; the firm has taken the time to get to know our business and act as true partners in their approach to matters‘.
‘The attorneys really listen and anticipate the needs of the client‘.
‘Lisa Haile is the most outstanding IP lawyer I’ve ever worked with – she is diligent, responsive, understands the practical business needs behind all the work she performs, and has an unparalleled scientific understanding of every issue we refer to her‘.
‘The DLA team has a number of outstanding lawyers on its team. Loren Brown is an excellent strategist and masterfully handles the most sensitive and difficult issues. Stephen Matthews is a welcome addition to the DLA team; he is an experienced litigator, trial lawyer and trusted advisor who skillfully handles complex litigation for life sciences companies. Danny Tobey and Lukas Pryzmusinski are physicians in addition to be being lawyers which enhances their ability to serve life sciences clients‘.
Adaptive Biotechnologies Corporation
- Defending Bristol-Myers Squibb and Pfizer in multi-district and state court litigation involving their blockbuster anticoagulant medication Eliquis.
- Representing Novo Nordisk in federal and state court litigation involving allegations that Victoza, as well as other incretin-based therapies approved for treatment of type-2 diabetes, causes pancreatic cancer and pancreatitis.
- Representing Chattem, the consumer products subsidiary of pharmaceutical company Sanofi, in a class action matter alleging false advertising and product defects relating to the Icy Hot Medicated No-Mess Applicator product manufactured and marketed by Chattem.
- Advised Adaptive Biotechnologies Corporation on its $345m initial public offering.
- Advised ResMed on its acquisition of MatrixCare and Propeler Health.
To some clients, Paul Hastings LLP is 'one of the top life sciences IP firms for litigation', and indeed, the firm is involved in many of the market’s most high-profile and complex cases. Demonstrating this, IP specialist Bruce Wexler and Eric Dittmann successfully represented Boehringer Ingelheim in the largest-ever Biologics Price Competition and Innovation Act (BPCIA) litigation against AbbVie relating to the filing of an application to create a biosimilar version of Humira. Further, Preston Ratliff is acting for Sucampo Pharmaceuticals in a patent infringement dispute against Sun Pharmaceuticals related to Sucampo’s Amitiza. The team hasalso recently been involved in a number of multimillion-dollar corporate, M&A and capital markets transactions, and data privacy and cyber security issues. New York-based Gary Giampietruzzi and Morgan Miller, who splits his time between Washington DC and London, are the names to note for investigations and white-collar defense matters. All individuals mentioned above are based in New York unless stated otherwise.
Other key lawyers:
‘They are wonderful to work with and achieve great results for their clients‘.
Johnson & Johnson
Merck & Co
Mitsubishi Tanabe Pharma Corporation
Sumitomo Dainippon Pharma
- Successfully represented Alkermes in a patent challenge for the company’s Orange Book-listed patent for VIVITROL, a drug used to treat addiction.
- Representing Actelion, a Johnson and Johnson company, in patent infringement lawsuits against Amneal Pharmaceuticals, Zydus Pharmaceuticals, and Aurobindo Pharma related to Actelion Opsumit.
- Represented Merck in a Hatch-Waxman patent infringement suit against Teva Pharmaceuticals regarding Merck’s innovative product Entereg.
- Successfully defended Boehringer Ingelheim in connection with BPCIA litigation relating to its biosimilar version of Humira against AbbVie.
- Advised GE Medical Systems Information Technologies on an underwritten secondary public offering of common stock of NeoGenomics.
Sidley Austin LLP
Weil, Gotshal & Manges LLP provides comprehensive legal advice to major clients such as Allergan, Eli Lilly, Johnson & Johnson, and Pacific Biosciences. The team has been especially active in high-profile patent litigation in 2019, having represented Johnson & Johnson's medical division, Ethicon, in patent infringement litigation before the ITC, as well as in two competitor cases and IPR proceedings against Intuitive Surgical protecting Ethicon’s key patents directed to its surgical stapling technology. Additionally, the team acted for Pacific Biosciences in patent infringement litigation relating to methods of sequencing DNA and RNA molecules using small protein holes against Oxford Nanopore Technologies. The practice group also advises multinational pharmaceutical companies on M&A, licensing and collaboration transactions, and antitrust litigation. The team is jointly led by litigators Elizabeth Weiswasser and Edward Reines, and transactional practitioner Michael Epstein. Also recommended are Jeffrey Osterman and recently promoted IP partner Derek Walter. The individuals mentioned above are spread across the firm's Silicon Valley and New York offices.
Johnson & Johnson
- Successfully represented Bio-Rad Laboratories and the University of Chicago in their patent infringement dispute against 10X Genomics.
- Acted for Plexxikon in inter partes review and post-grant review proceedings filed by Novartis seeking to invalidate key Plexxikon patents.
- Represented Janssen, Johnson & Johnson’s pharmaceutical division, in a false advertising dispute brought by Novartis.
- Advising Allergan on the antitrust aspect of its $63bn acquisition by AbbVie.
- Advising Walgreens Boots Alliance on a number of healthcare-related acquisitions, collaborations and strategic investments.
Mayer Brown's clients include start-ups, major pharmaceutical, biotech and medical device companies, financial institutions, funds and other investors. The 65-partner team is spread across the firm's Chicago, New York, Washington DC, San Francisco and Palo Alto offices. Gary Hnath (Washington DC), Joseph Mahoney (Charlotte), James Ferguson (Chicago), and Lisa Ferri and Brian Nolan (both in New York) all have expertise in IP litigation and counseling. Also in the litigation space, Henninger Bullock in New York represents life sciences clients in product liability, licensing and supply disputes. On the transactional front, Reb Wheeler and David Carpenter handle a mix of M&A, private equity, securities, and other corporate matters. Co-head of global capital markets practice Anna Pinedo and Phyllis Korff are also recommended. The team is also particularly experienced in acting for Israeli life sciences companies, advising on a range of multimillion-dollar corporate, M&A, and capital markets transactions.
Other key lawyers:
Merck & Co.
Nestlé Health Science
St. Jude Medical
Panaxia Pharmaceutical Industries
- Advised InMode on its $77m initial public offering.
- Advised BiomX on its reverse merger with Chardan Healthcare Acquisition Corp.
- Acted for Bristol-Myers Squibb Company, as IP counsel, in its $74bn acquisition of Celgene Corp.
- Successfully represented HemoSonics before the Patent Trial and Appeal Board (PTAB) relating to its first FDA-approved product, the Quantra QPlus System.
- Defended Medtronic in product liability cases pertaining to the safety of an implantable cardioverter defibrillator.
McDermott Will & Emery LLP's life sciences practice stands out for its strong patent litigation offering. In addition, the firm handles commercial litigation, corporate and M&A transactions and regulatory matters. Kristian Werling and Stephen Bernstein jointly lead the team from its Chicago and Boston offices. Also recommended are Silicon Valley-based IP litigator William Gaede; Sarah Hogan in Boston, who advises on the structuring and negotiating IP licenses, strategic collaborations and other complex commercial transactions; Washington DC-based FDA-regulatory expert Vernessa Pollard; and Paul Radensky, who specializes in regulatory matters. The team was recently strengthened by the hire of senior advisor Scott Bernstein, who joined from Kite Pharma, and focuses on IP and licensing mandates.
Other key lawyers:
‘The team has great knowledge of the industry and understanding of the issues affecting companies in the healthcare industry‘.
‘Edward Zacharias gives practical advice‘.
Impax Laboratories/Amneal Pharmaceuticals
Lantheus Medical Imaging
- Assisted Origenis with the spin-off several central nervous system assets into a new US company (Newco), coupled with a venture capital financing of the Newco, and a multi-year master service agreement for ongoing services to Newco.
- Advised Bemis on its $6.8bn merger with Amcor, an Australian global flexible packaging company that develops and produces packaging for pharmaceutical and medical-device products.
- Secured a major jury trial victory for Amgen in its long-fought battle with Sanofi and Regeneron Pharmaceuticals over the new generation of “blockbuster” drugs proven to lower “bad” cholesterol.
- Represented two defendants, Impax Laboratories and Amneal Pharmaceuticals in the generic pharmaceuticals pricing antitrust litigation.
- Acted for HanAll Biopharma in relation to Immunovant’s merger with a Nasdaq-traded special purpose acquisition corporation in a transaction which brings $100m into Immunovant for the development of HanAll’s licensed technology.
Morrison & Foerster LLP assists global pharmaceutical companies and emerging industry disruptors with matters involving patenting software and AI-related life sciences inventions, data licensing, data privacy issues and FDA approvals for data-driven diagnostics and medical devices. The firm established its Boston office in February 2019 with the addition of a 23-person finance group including corporate partner Ori Solomon, who joined from Proskauer Rose LLP; it also saw the formation of its FDA regulatory and life sciences compliance practice, led by Bethany Hills, who joined from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Michael Ward heads the global life sciences group from the Boston office, which includes Catherine Polizzi, a key advisor to Celgene Corporation, which she advised on the $2.9bn acquisition of Abraxis BioScience, and the acquisition by Bristol Myers Squibb. Other key figures include Kate Murashige, a key name to note for patent prosecution and litigation; Palo Alto-based IP specialist Janet Xiao, who has particular expertise in China-related matters; and Jim Krenn, whose recent highlights include advising Rakuten Medical on a series of fundraising transactions.
Other key lawyers:
Ally Bridge Group
ARCH Venture Partners
Washington University in St. Louis
- Successfully defended Genentech in a patent infringement dispute involving Genentech’s pioneering breast cancer treatment Kadcyla.
- Advised Rakuten Medical on raising over $470m in equity capital over several rounds of financing.
- Representing medical device company Nevro Corp in suing Boston Scientific Corp in California federal court for alleged infringement of Nevro patents covering spinal cord stimulation technology for the treatment of chronic pain.
- Advising Triastek on building its patent portfolio, and successfully obtained a number of issued patents for the company covering its key platform technology and novel dosage forms.
- Advised Carlsmed, a San Diego-based medical technology company, in its merger with Seattle-based spine imaging system company Precisive Surgical to offer the industry’s first personalized surgical workflow platform.
Norton Rose Fulbright's life sciences department is divided into teams handing product liability, merger clearance and antitrust litigation, IP, and data privacy matters. Austin-based chief operating officer Stacey Martinez specializes in product liability cases and matters involving exposure to toxic substances, while Debbi Johnstone in Houston has a wealth of experience in M&A, joint venture, compliance and reimbursement matters. Dallas-based D’Lesli Davis is noted for mass tort and product liability cases, and Carol Poindexter in Washington DC has extensive regulatory and litigation experience. The team also handles false advertising matters, and is representing ProvePharm in its false advertising claims against Akorn pertaining inaccurate labeling and marketing relating to methylene blue and its use to treat methemoglobinemia.
‘The antitrust team let by Robin Adelstein is uniquely pragmatic. She attracts top talent to the group and is able to bring in interesting cases and achieve optimal results. Moreover, the team, through Adelstein has a clear focus on antitrust in the life sciences space, giving them an advantage over some peers who focus purely on antitrust, without the very specific focus on life sciences. The team also appropriately staffs cases, but there is always significant oversight by partners‘.
‘Robin Adelstein is at the top of her game. She brings the pragmatism of an in-house lawyer, spending a large amount of her career working for large companies, including as the United States GC for a large pharmaceutical business. She is tireless in her efforts and understands the needs from an in-house perspective. Antitrust is not always pragmatic, but she brings this practicality to the practice, because she understands how a business needs to operate to be successful. She is always available if necessary‘.
Bausch Health Companies
Bausch Health Americas (a subsidiary of Bausch Health Companies)
- Advised Medidata Solutions, a clinical cloud solutions company, on its sale by public merger to French software company Dassault Systèmes in an all-cash deal worth $5.8bn on an enterprise value basis.
- Representing ProvePharm in its false advertising claims against Akorn.
- Representing Sierra Oncology and its officers and directors in a Rule 10b-5 class action suit in the Southern District of New York and in a companion Section 11 class action in San Mateo, California relating to the discontinuation of clinical trials for an experimental cancer treatment.
- Acted for XBiotech USA, a therapy development-stage pharmaceutical company with a novel anti-cancer treatment in Phase III clinical trials, in a securities class action filed by stockholders alleging violations of Rule 10b-5 and Section 11.
- Represented Boehringer Ingelheim in multi-district antitrust litigation that combines eleven proposed class actions alleging a pay-for-delay scheme over a generic version of a stroke drug, Aggrenox.
O'Melveny & Myers LLP's life sciences industry group handles the full range of work for pharmaceutical, medical devices and diagnostics companies, but is particularly well known for its strengths in IP litigation and class actions. The practice is co-led by Los Angeles-based Richard Goetz, who handles mass tort and product liability litigation; New York-based Ross Galin and Lisa Pensabene, who focus on white-collar defense and government investigations, and Hatch-Waxman litigation and trade secret disputes, respectively; and San Francisco-based Scott Elliott, who is recommended for major financing, corporate and securities transactions. Goetz recently acted for Johnson & Johnson and its subsidiary Janssen Pharmaceuticals in the Oklahoma opioids litigation, the first opioid case to go to trial.
Johnson & Johnson
Novartis Pharmaceuticals Corporation
Shanghai Haohai Biological Technology Co.
TPG Biotechnology Partners
- Representing Onyx Therapeutics in a Hatch-Waxman litigation enforcing patents relating to multiple myeloma drug Kyprolis.
- Representing ViiV Healthcare and Shionogi in litigation to enforce patents relating to HIV treatments, Tivicay and Triumeq.
- Represented Asieris MediTech in negotiating and securing a cross-border licensing agreement with Norwegian company Photocure ASA for the world-wide development and commercialization of Cevira, a treatment for HPV induced cervical precancerous lesions.
- Acted for Glaukos Corp., an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, in its acquisition of Avedro.
- Advised Progenics on its definitive merger agreement with Lantheus Holdings.
Proskauer Rose LLP is particularly experienced in handling IP strategy, patent litigation and corporate transactions, with a notable strength in the biosimilar-related matters. Among its recent caseload, life sciences group chair Siegmund Gutman, who represents clients before trial and appellate courts as well as arbitration panels, acted for Amgen in high-profile patent litigation concerning Amgen's development and commercialization of a biosimilar to Genentech's Acastin. Fangli Chen and Steven Bauer are also recommended for patent infringement and trade secrets litigation. New York-based Robert Cantone and Daryn Grossman are contacts for corporate and financing transactions.
‘They are able to quickly assess a legal issue and determine its level of complexity for us. They will offer to handle it for us, or if appropriate, provide us the tools to handle it ourselves. They are our go-to firm for discovery responses, especially third party subpoenas, helping us to avoid huge and costly productions‘.
‘Siegmund Gutman takes a keen interest in how our international company operates. He understands our strengths and weaknesses and is quick to point out potential risk management gaps, which we greatly appreciate. His advanced knowledge of the life science industry, especially in chemistry, gives great comfort to our R&D executives and scientists. He is also particularly sensitive to changes in patent laws both in the US and in Europe‘.
‘Associate David Hanna is super responsive and is very detail oriented‘.
Johnson & Johnson
Various Life Sciences Companies
- Defending Johnson & Johnson in a case alleging its talcum powder products caused the plaintiff’s peritoneal mesothelioma.
- Handling Akebia’s worldwide patent portfolio covering vadadustat, a drug which is in Phase 3 clinical trials for treatment of anemia due to chronic kidney disease.
- Advising Shire on developing patent portfolios that provide protection for more than 20 programs and products including their biggest lead biologic products Elaprase and Cinryze.
- Representing Monsanto and its parent company, Bayer, in a California jury trial alleging that the use of Monsanto’s herbicide, RoundUp, caused the plaintiff’s non-Hodgkin’s lymphoma.
- Acting for Absorption Pharmaceuticals in a high-profile dispute against Reckitt Benckiser involving claims of fraud, trade secret misappropriation, tortious interference with contractual relations.
Reed Smith LLP
Reed Smith LLP is particularly experienced in advising on big-ticket transactions and venture capital investment in the life sciences sector, including assisting both investors and companies seeking funding, and biotechnology companies in corporate and commercial matters including high-value M&A deals, venture capital investments and licensing and collaboration agreements. Diane Frenier and Betty Yan focus on corporate transactions, and Michael Sanders is a key advisor to the firm's start-up clients, development stage companies, and venture investors investing in those companies. Melissa Geist and Scot Hasselman, based in Princeton and Washington DC respectively, are also recommended. The group expanded its life sciences practice with the opening of a new office in Austin, having hired a number of regulatory practitioners from Norton Rose Fulbright.
Skadden, Arps, Slate, Meagher & Flom LLP
Skadden, Arps, Slate, Meagher & Flom LLP is very experienced in major M&A, restructuring, licensing, and financing transactions. The team has also shown its strength in product liability cases, investigations and securities litigation. Graham Robinson in Boston and Paul Schnell in New York handle major corporate and M&A transactions. Washington DC-based litigators John Beisner and Jessica Miller are recommended for product liability matters; FDA specialists Jennifer Bragg, Maya Florence and enforcement expert John Bentivoglio are further names to note.
Rite Aid Corporation
Exact Sciences Corporation
- Advised Centene Corporation on its $17.3bn merger with WellCare Health Plans.
- Assisting Array BioPharma with its $11.4bn acquisition by Pfizer.
- Advising Gilead Sciences on its $5.1bn transaction with Galapagos involving a 10-year global research development collaboration with, and equity investment in, Galapagos. Also advising on its $198m sale of its Momelotinib myelofibrosis treatment drug to Sierra Oncology.
- Represented Merck and Pfizer in a patent challenge related to a cancer immunology drug that the companies are co-developing.
- Representing Ethicon in a number of personal injury actions involving the company’s Gynecare trans-vaginal mesh product.
WilmerHale excels in advising emerging and growth-stage life sciences companies and investors on fundraising matters at all stages of a company's development. The team recently advised Schrödinger, a privately held company that specializes in drug discovery through advanced molecular simulations, in its $85m Series E funding, and also handled earlier-stage financing rounds for Ribon Therapeutics and Ribometrix. The team also handles a steady flow of high profile patent litigation, having recently represented Bristol-Myers Squibb and Pfizer against 25 generic companies in Hatch-Waxman litigation concerning the Orange Book-listed patents for the plaintiffs' anticoagulant drug product, Eliquis. Boston-based Stuart Falber and Brian Johnson in New York have experience of a broad range of transactions during the life cycle of a life sciences company; Steven Barrett specializes in technology transactions; Lisa Pirozzolo and trial lawyer Robert Gunther handle IP litigation; and Kirk Nahra who joined from Wiley Rein LLP specializes in privacy and cyber security issues.
Other key lawyers:
‘WilmerHale consistently delivers pragmatic, actionable advice and flawless work product. They also do an exceptional job of keeping me updated on their work streams without bogging me down in needless minutiae. They react quickly, calmly, and effectively‘.
‘Dave Bassett is an excellent strategist and writer, and he’s great on his feet too‘.
‘Lisa Pirozzolo is meticulous. She is also a fantastic writer and oral advocate‘.
‘Emily Whelan is the best issue-spotter I have ever worked with. Having Emily on my case team practically assures that there will be no unfortunate surprises‘.
Becton, Dickinson and Company
Memorial Sloan Kettering Cancer Center
Roche Molecular Systems
Roche Sequencing Solutions
Thermo Fisher Scientific
- Advising Medtronic and its subsidiaries on its €6.9bn and €5bn public offerings of euro-denominated senior notes.
- Acted for Thermo Fisher Scientific, a multinational biotechnology product development company, in the $1.14bn sale of its Anatomical Pathology business to PHC Holdings Corporation.
- Handling biosimilar patent litigation and related IPR matters for Genentech involving Herceptin, which has been approved to treat certain types of breast and gastric cancer.
- Defending CSL Behring LLC, CSL Behring GmbH and CSL Recombinant Facility AG in the patent infringement claim filed by Bioverativ, a spin-off of Biogen relating to the importation of Idelvion, a treatment for hemophilia B.
- Representing Akebia in Hatch-Waxman litigation relating to 14 patents covering its drug for kidney disease against four generic companies.
Debevoise & Plimpton LLP's recent caseload features a number of cross-border disputes including commercial and false advertising litigation. The team has also advised financial advisors to major pharmaceutical companies in several multibillion-dollar M&A deals. The team is led by five senior partners: Andrew Bab and Kevin Rinker focus on M&A and private equity transactions, Mark Goodman and Maura Monaghan specialize in commercial litigation, and Paul Rubin is the name to note for FDA regulatory matters who is representing a life sciences company on medical device regulatory issues involving genetic testing, including FDA regulation and device approval. Named individuals are based in New York and Washington DC.
Other key lawyers:
Hospital Corporation of America
Allergan (formerly Forest Laboratories)
Johnson & Johnson
Nestlé Skin Health
Emblem Health / Group Health
Memorial Sloane Kettering Cancer Center
Welsh, Carson, Anderson & Stowe
JP Morgan Securities
- Defended Foundation Medicine, a leading cancer diagnostic company in a critical false-advertising litigation filed by Guardant Health.
- Advising JP Morgan Securities as financial advisor to Allergan on its sale to AbbVie.
- Advising Guggenheim Securities and Morgan Stanley & Co. as financial advisors to Pfizer in connection with Pfizer’s $11.4bn acquisition of Array BioPharma.
- Successfully represented Allergan in a number of litigation matters including the Celexa and Lexapro Marketing and Sales Practices Multidistrict litigation and in the dismissal a qui tam complaint brought under the False Claims Act relating to the marketing of the pharmaceutical drug Namenda.
- Representing certain former directors and shareholders of Purdue Pharma regarding prescription opioid litigation in various forums across the country, including a federal multi-district litigation and actions brought by states attorneys general.
Gibson, Dunn & Crutcher LLP
Gibson, Dunn & Crutcher LLP excels in product liability and IP litigation, M&A and structured financing transactions, and regulatory and government enforcement matters. The team is jointly led by New York-based IP specialist Jane Love, who successfully acted for Novatis in a high profile Hatch-Waxman litigation relating to its sclerosis drug Gileya, and Ryan Murr, who is based in San Francisco, and recently acted for Arrowhead Pharmaceuticals in its $3.7bn collaboration with Johnson & Johnson. Dallas-based Tracey Davies is another name to note; she has experience representing innovator pharmaceutical and biologics clients in jury and bench trials across a diverse range of matters including patent litigation, breach of contract and false claims act cases.
Other key lawyers:
- Advised Sloan Pharma, a subsidiary of US WorldMeds Holdings, in its sale of Zelnorm (tegaserod maleate), a treatment for IBS-C, to Alfasigma USA.
- Advised Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, on its $350m public offering of common stock.
- Represented Amgen in the antitrust litigation filed by Cipla, a competitor, as well as putative classes of direct and indirect purchasers.
- Representing Novartis in a large Hatch-Waxman case in Delaware involving a Novartis patent directed to a method for treating multiple sclerosis.
- Acted for Roivant Sciences in a licensing and collaboration transaction with Cincinnati Children’s Hospital Medical Center for the formation of a new entity, Aruvant Sciences.
Kirkland & Ellis LLP acts for pharmaceutical and biotechnology companies, as well as private equity and venture capital investors. The team was instructed on a number of recent mega M&A, having advised AbbVie on its $63bn acquisition of Allergan, and acting for Bristol-Myers Squibb Company in the acquisition of Celgene Corporation. Nationally recognized trial lawyer James Hurst (Chicago) and trial and appellate lawyer Jay Lefkowitz (New York) are the key names to note, and jointly lead the team with New York-based IP litigators Patricia Carson and Leora Ben-Ami. Recent trial wins have included Hurst successfully representing Alere in a patent infringement case, and also representing Flexus Biosciences (now a Bristol-Myers Squibb subsidiary) in a trade secret trial.
Association for Accessible Medicines
Bristol-Myers Squibb Co.
Johnson & Johnson
Teva Pharmaceutical Industries
WellCare Health Plans
- Advised WellCare Health Plans on its $17.3bn acquisition by Centene Corporation.
- Advised Samumed on its exclusive license agreement with United Therapeutics Corporation.
- Acted for GlaxoSmithKline in combining its health business with Pfizer and establishing a joint venture.
- Represented AbbVie in a multi-defendant antitrust case regarding its Humira.
- Acting for Johnson & Johnson and its subsidiary, Johnson & Johnson Consumer in two negligence and product liability disputes relating to talc powder products.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.'s team is jointly led by Boston-based Jonathan Kravetz and William Whelan, who handle a mix of venture capital financing, M&A, and securities and capital markets transactions. Recent work has also included collaboration and licensing mandates, having advised BeiGene on its global strategic oncology collaboration with Amgen for the commercialization and development of Amgen’s Xgeva, Kyprolis, and Blincyto and the joint global development of 20 oncology assets in Amgen’s pipeline. Another name to note is San Francisco-based Terri Shieh-Newton, who focuses on patent prosecution, portfolio management and post-grant proceedings.
Other key lawyers:
Johnson & Johnson
- Acted for Biogen in the $900m sale of a biologics manufacturing facility to FujiFilm Corporation.
- Advised BeiGene on its global strategic oncology collaboration with Amgen for the commercialization and development in China of Amgen’s XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) and the joint global development of 20 oncology assets in Amgen’s pipeline, with BeiGene responsible for development and commercialization in China.
- Represented Keryx Pharmaceuticals, now a subsidiary of Akebia Therapeutics, in a putative class action alleging securities fraud pending in federal court and in related state court derivative cases.
- Acted for Spero Therapeutics in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop Spero’s orally administered SPR720 for the treatment of tuberculosis.
- Advised ArQule on its negotiation of an exclusive license agreement with Sinovant Sciences and Roivant Sciences pursuant to which ArQule granted Sinovant an exclusive license to develop, manufacture and commercialize its FGFR inhibitor, derazantinib in Greater China.
Clients praise Orrick, Herrington & Sutcliffe LLP's 'laser sharp focus, client-oriented approach, and efficient and very quick responses'. The team is particularly strong in mass tort and product liability cases, having recently secured three defense verdicts for Johnson & Johnson in its high-profile talcum power cases. It also maintains a steady flow of venture capital, licensing and M&A transactions. Scott Iyama heads the 35-partner group from Silicon Valley and is experienced in financing, M&A, and partnering transactions, as is New York-based Stephen Thau. Kathleen O’Connor focuses on product liability and commercial claims, licensing and co-development disputes and government investigations.
Other key lawyers:
‘Laser sharp focus. Very client oriented. Efficient and very quick responses‘.
‘Friendly, flexible, and reasonable in billing hours and costs‘.
‘Lily Becker has a pleasant personality that makes her easy to work with from a client perspective, yet she is tough and aggressively represents our firm’s best interests‘.
‘David Schwartz is always spot on‘.
Johnson & Johnson
Zimmer Biomet Holdings
Twist Biosciences Corporation
Vanda Pharmaceuticals Inc.
Varian Medical Systems
- Representing Johnson & Johnson as national trial, appellate and coordinating counsel in its massive docket of talcum powder litigation.
- Advised Twist Bioscience on its IPO and follow-on offering.
- Advised Arsenal Biosciences, a Massachusetts-based startup that operates a platform technology company designed to develop novel polymer-based foams and fibers, on its Series A financing.
- Acted for Varian Medical Systems in a number of multimillion-dollar corporate venture capital investments.
- Advised Bayer on its strategic collaboration with biopharmaceutical company Arvinas to leverage Arvinas’ protac protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological and gynecological diseases.
Paul, Weiss, Rifkind, Wharton & Garrison LLP represents pharmaceutical companies in domestic and international litigation, M&A transactions, and is particularly well versed in handling complex patent litigation. Kenneth Gallo and Nicholas Groombridge, based in Washington DC and New York respectively, are well recognized litigators and trial lawyers with notable experience handling high-value patent disputes. Catherine Nyarady and Eric Alan Stone are also key names to note. The team counts Smith & Nephew as a major client which it assisted with its $660m acquisition of Osiris Theapeutics. Other highlights also include advising General Electric Company on the $21.4bn sale of its BioPharma business to Danaher corporation, and representing Johnson & Johnson in an appeal in the USPTO involving the application of the inherency doctrine to invalidate patent claims.
‘Catharine Nyarady is good at communicating with the clients and the courts‘.
Becton, Dickinson & Co.
General Electric Company
Johnson & Johnson
Smith & Nephew
Elanco Animal Health
- Defending biotech company 10X Genomics in an ITC dispute with Bio-Rad Laboratories and with Lawrence Livermore National Security regarding an alleged patent infringement claim.
- Represented Amgen in litigation regarding Apotex’s application to market biosimilars of Amgen’s Neupogen and Neulasta.
- Successfully represented Becton, Dickinson and Company in the dismissal of a multibillion-dollar antitrust class action.
- Acted for Channel Medsystems in a dispute pertaining to Boston Scientific’s termination of their merger agreement.
- Advised Elanco nimal Health Incorporated on its $7.6bn acquisition f the animal health business of Bayer.
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati has a track record of acting for companies in the biotechnology, medical devices and pharmaceuticals sectors. Miranda Biven and Kenneth Clark split their time between San Diego and Palo Alto, and are recommended for partnering and licensing and M&A transactions, respectively. Douglas Carsten has experience litigating major patent cases. Palo Alto-based Lowell Segal and IP specialist Vern Norviel are additional contacts.